



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

23 Mar 2020 (#13)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • **Stellenbosch Campus** lizelk@sun.ac.za

Important Notice

[NOT-OD-20-087](#) Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19. The purpose of this notice is to provide guidance outlining the flexibilities available to recipients conducting NIH-funded clinical trials and human subject studies, that are impacted by the [declared public health emergency](#) for COVID-19. NIH recognizes the significant effects that this emergency is having on NIH-funded clinical trials and other human subjects studies. First and foremost, NIH is concerned about the safety and welfare of human subject participants and research staff. Institutions should take all steps necessary to ensure the safety of all human participants and research staff involved in NIH-funded clinical trials and human subjects studies. At this time, NIH encourages recipients to consult with their IRB and institutions about potential measures to protect participants and research staff.

[NOT-CA-20-034](#) Notice of Special Interest: Alcohol and Cancer Control. This Notice highlights interest in receiving investigator-initiated grant applications addressing the effects of alcohol on human health across the cancer control continuum. Alcohol is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC). Worldwide, 5.5% of newly diagnosed cancer cases and 5.8% of cancer deaths are attributable to alcohol use, including 5.6% of cases and 4.0% of deaths in the United States (U.S.). Epidemiological and biological research has established that alcohol consumption increases the risk of at least seven different cancers in humans, including mouth and oropharyngeal, laryngeal, esophageal, female breast, colorectal, stomach, and liver cancer. Alcohol use is estimated to be the third largest contributing risk factor for cancer in women and the fourth largest for men in the U.S., following cigarette smoking, ultraviolet (UV) radiation exposure (men), and excess body weight.

1. Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PA-20-141](#)

Type: R34

Application Due Date: [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention or treatment. For the purposes of this FOA, "intervention" is defined to include behavioral, social, or structural approaches, as well as combination biomedical and behavioral, social, or structural approaches that prevent acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected, or both.

Budget: Direct costs are limited to \$450,000 over the entire project period, with no more than \$225,000 in direct costs in any single year. The total project period for an application submitted in response to this funding opportunity may not exceed three years.

2. Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-140](#)

Type: R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) .Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases.

Budget: NIDDK intends to fund approximately 10 awards, corresponding to a total of \$2.0 million, for Fiscal Year 2021. Future year amounts will depend on annual appropriations. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

3. Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-027](#)

Type: R01

Application Due Date: July 31, 2020; July 30, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult (AYA) cancer survivors. Specifically, this FOA solicits mechanistic, observational, and intervention applications that focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up care (e.g. access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors.

Budget: NCI intends to commit \$50 million total across the fiscal years (FYs) 2021 and 2022 to fund up to 14 awards from both the RFA-CA-20-027 and RFA-CA-20-028 (R21). Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Genomic Predictors of Pregnancy Loss (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HD-21-005](#)

Type: R01

Application Due Date: July 30, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support studies which utilize emerging genomic technologies to identify variants which predict risk for pregnancy loss in subsequent pregnancies beyond standard karyotype approaches.

Budget: NICHD and partner components intend to commit \$3,000,000 in FY2021 to fund 2-3 awards. Application budgets are limited to a maximum of \$1,000,000 per year in direct costs but need to reflect the actual needs of the proposed projects. A maximum project period of 5 years is allowed.

5. Novel Synthetic Nucleic Acid Technology Development (Clinical Trial not allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HG-20-014](#)

Type: R01

Application Due Date: June 24, 2020; February 1, 2021; October 1, 2021; June 24, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits R01 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Large progress in this area has the potential to catalyze scientific advances relevant to the mission of NIH, NHGRI and the field of genomics.

Budget: NHGRI intends to commit \$2,000,000 in FY21, 22 and 23 to fund 2-4 awards yearly. The actual number of awards and amount are contingent on NIH appropriations, and the submission of a sufficient number of meritorious applications. An applicant may request direct costs of up to \$700,000 per year. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The scope of the proposed project should determine the project period. The maximum project period is 3 years

6. Novel Synthetic Nucleic Acid Technology Development (Clinical Trial not allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HG-20-015](#)

Type: R21

Application Due Date: June 24, 2020; February 1, 2021; October 1, 2021; June 24, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

Budget: NHGRI intends to commit \$1,000,000 in FY21, 22 and 23 to fund 3-5 awards yearly. The actual number of awards and amount are contingent on NIH appropriations, and the submission of a sufficient number of meritorious applications. An applicant may request up to \$200,000 per year and no more than \$400,000 in direct costs for the entire project period. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The scope of the proposed project should determine the project period. The maximum project period is 3 years

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: [Christa](mailto:cdevries@sun.ac.za)
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: [Lizel](mailto:lizelk@sun.ac.za)
e: lizelk@sun.ac.za | t: +27 21 808 2105